VERU

Veru Inc. (VERU) | Rumor.io

Veru

VERU

Attention (50-day avg)0%

Attention rank (50-day avg)#2,993

Bullish sentiment (50-day avg)80%

Price to earnings ratio0.41

Market capitalization43.1M

Earnings per share-0.61

Dividend yield (TTM)11.1%

Revenue (annual)0

Net income (annual)-22.7M

Social

What share of all stock conversation is about VERU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 8

Veru Inc. (VERU) announced positive preclinical data for its oral sabizabulin, showing potent anticancer activity in human daraxonrasib-resistant pancreatic cancer.
The company is advancing oral sabizabulin into a planned Phase 2 clinical trial, with a pre-IND meeting with the FDA scheduled for Q4 2026.
The trial's success will be a significant milestone for VERU, but investors may treat the news with caution due to the company's cash runway and pipeline costs, which may demand additional capital.

Generated by AI

Sentiment

Of the messages about VERU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	81.82% 0	58.62% -24.67
Bearish	—	—	18.18% 0	41.38% +24.67

Bullish· Jun 11

The company has a low publicly tradable supply, causing extreme liquidity constraints, which could lead to a price surge.
The short interest in the stock is extremely high, with off-exchange short volume exceeding the entire float by 6.4 times, indicating a potential short squeeze.
The stock is experiencing a severe supply drain, with the lending pool inventory running low and the cost to borrow interest rate peaking, which could lead to a breakout and a significant price increase.

Bearish· Jun 11

The borrow pool for $VERU has decreased significantly, potentially indicating a shortage of shares available for short selling.
The borrow fee for $VERU has increased, suggesting a higher demand for shares and potentially signaling a bearish trend.
There is a large short position in $VERU, with many traders expecting the price to continue falling, and some even predicting a significant price drop.

Generated by AI

Topics

Of the messages about VERU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	12.5%	60.57%
Technical Analysis	—	—	87.5%	33.42%
Earnings	—	—	0%	1.31%
Analysts	—	—	0%	2.87%
Controversies	—	—	0%	1.31%
Macro	—	—	0%	0.52%

Earnings· Feb 9

VERU reported a Q1 loss of $0.46, missing consensus estimates by $0.08.
Revenues fell 82% to $2.5M, missing estimates by $2.56M.
The company has approximately 2 quarters of cash left, with cash and cash equivalents totaling $46.9M.

Analysts· Apr 12

Oppenheimer analyst Leland Gershell raised the price target on Veru to $36 from $25 and maintains an Outperform rating on the shares.
HC Wainwright & Co. analyst Yi Chen maintains Veru with a Buy and raises the price target from $21 to $24.
Veru's price target has been raised by multiple analysts, including Oppenheimer to $36, HC Wainwright to $24, and Jefferies to $33.

Announcements· Jun 4

Veru Inc. (VERU) has entered into a clinical supply agreement with Novo Nordisk (NVO) to support Veru's upcoming Phase 2b PLATEAU study in obesity, evaluating Veru's oral investigational therapy enobosarm in combination with Wegovy.
The agreement grants Novo Nordisk the right of first negotiation for future combinations of enobosarm with GLP-1 medications, and Novo will provide Wegovy for free to Veru's Phase 2b trial.
Canaccord has maintained a Buy rating on Veru with a $25 price target, calling the news a "significant event" that shows enobosarm has "grabbed the attention of one of the two players in the obesity market".

Controversies· Nov 9

An FDA Advisory Panel voted 8-5 against backing Veru's Covid-19 pill, citing concerns over the clinical trial design and data.
The FDA has raised several uncertainties, including baseline imbalances in standard-of-care therapies, potential for unblinding events, and uncertain effects of goals of care decisions on all-cause mortality.
Despite some qualms, FDA staff are considering an EUA with a requirement for another RCT in the same population as a condition of the authorization.

Technical Analysis· Jun 4

$VERU is in a falling wedge pattern and needs to break back over $6 for a potential push to the upside, with a target of $6.5+ above $6.
The 9 EMA trend for $VERU looks ready for a move, with an explosive breakout potentially close.
The daily gap fill for $VERU has been hit, and the stock is ready for a move, with a target of $20+ if it breaks through key resistance levels.

Generated by AI

Community

Of the messages about VERU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	52.17%	41.67%
Newcomers	—	—	47.83%	58.33%

Regulars· Jun 4

$VERU has entered a clinical supply agreement with Novo Nordisk to evaluate the combination of Enobosarm with Wegovy, a $15–$20 billion annualized product.
The news is considered a "significant event" by Canaccord, which reiterated a Buy rating and $27 price target for Veru.
Veru's stock price surged 146% due to the announcement, and the company is expected to break out of resistance with sizzling volume and a rocket RSI.

Newcomers· Jun 5

Many newcomers are focused on the stock's recent surge, with some mentioning the company's partnership with Novo Nordisk and the potential for enobosarm combination therapies.
New investors are weighing in on the stock's potential, with some sharing their own experiences of buying and selling VERU, and others expressing hesitation due to the stock's volatility.
VERU's business model and recent market activity are being explored in depth by some newcomers, who are looking for a deeper understanding of the company's role within the healthcare sector and potential for long-term development.

Generated by AI

--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant met

22d agoYahoo Finance

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming 2026 Cantor Global Healthcare Conference, in New York City, New York, on September 9, 2026 from 2:10 pm – 2:40 pm Easte

28d agoYahoo! Finance Canada

Veru (VERU) Q3 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Earnings call transcript: Veru posts Q3 2026 EPS beat as PLATEAU trial advances

1mo agoInvesting.com

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial -- -- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent

1mo agofinance.yahoo.com

Veru completes enrollment of obesity drug trial with 239 patients

1mo agoInvesting.com

Also Discussed

Investors talking about VERU also mention

#	Name	Attention
1	Nkarta, Inc.NKTX	0%0
2	United Maritime CorporationUSEA	0%0
3	SIGA Technologies Inc.SIGA	0%new
4	AlloVir, Inc.ALVR	0%0
5	ALLG - Allego N.V.	——
6	Lixte Biotechnology Holdings Inc.LIXT	0%new
7	Nutex Health Inc.NUTX	0%new
8	Longeveron Inc. Class A Common StockLGVN	0%0
9	IGMS - IGM Biosciences, Inc.	——
10	FRGE - Forge Global Holdings, Inc.	——

Veru Inc.

Healthcare
Biotechnology

Veru Inc. is a biopharmaceutical company focused on developing and commercializing novel small‑molecule therapies for cardiometabolic and inflammatory diseases. The company’s lead program centers on enobosarm, an oral selective androgen receptor modulator being evaluated to mitigate loss of muscle mass and function in patients undergoing weight loss treatment with GLP‑1–based therapies, aiming to support higher-quality weight reduction by preserving lean tissue. Veru Inc. is also advancing sabizabulin, an oral microtubule disruptor with broad anti-inflammatory properties under development for chronic inflammation associated with atherosclerotic cardiovascular disease and related conditions. In addition, the company maintains programs in oncology and acute respiratory distress syndrome, with late-stage development assets targeting breast and prostate cancer and viral-related ARDS. Veru Inc. currently generates revenue primarily from the United States, South Africa, and other international markets through its commercial sexual health products, including ENTADFI for benign prostatic hyperplasia and the FC2 Female Condom (Internal Condom). Headquartered in Miami, Florida, Veru Inc. operates as a single business segment within the healthcare and biotechnology industry.

Website

Location

2916 North Miami Avenue

Miami, FL, 33127

United States

Social

What share of all stock conversation is about VERU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 8

Veru Inc. (VERU) announced positive preclinical data for its oral sabizabulin, showing potent anticancer activity in human daraxonrasib-resistant pancreatic cancer.
The company is advancing oral sabizabulin into a planned Phase 2 clinical trial, with a pre-IND meeting with the FDA scheduled for Q4 2026.
The trial's success will be a significant milestone for VERU, but investors may treat the news with caution due to the company's cash runway and pipeline costs, which may demand additional capital.

Generated by AI

Sentiment

Of the messages about VERU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	81.82% 0	58.62% -24.67
Bearish	—	—	18.18% 0	41.38% +24.67

Bullish· Jun 11

The company has a low publicly tradable supply, causing extreme liquidity constraints, which could lead to a price surge.
The short interest in the stock is extremely high, with off-exchange short volume exceeding the entire float by 6.4 times, indicating a potential short squeeze.
The stock is experiencing a severe supply drain, with the lending pool inventory running low and the cost to borrow interest rate peaking, which could lead to a breakout and a significant price increase.

Bearish· Jun 11

The borrow pool for $VERU has decreased significantly, potentially indicating a shortage of shares available for short selling.
The borrow fee for $VERU has increased, suggesting a higher demand for shares and potentially signaling a bearish trend.
There is a large short position in $VERU, with many traders expecting the price to continue falling, and some even predicting a significant price drop.

Generated by AI

Topics

Of the messages about VERU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	12.5%	60.57%
Technical Analysis	—	—	87.5%	33.42%
Earnings	—	—	0%	1.31%
Analysts	—	—	0%	2.87%
Controversies	—	—	0%	1.31%
Macro	—	—	0%	0.52%

Earnings· Feb 9

VERU reported a Q1 loss of $0.46, missing consensus estimates by $0.08.
Revenues fell 82% to $2.5M, missing estimates by $2.56M.
The company has approximately 2 quarters of cash left, with cash and cash equivalents totaling $46.9M.

Analysts· Apr 12

Oppenheimer analyst Leland Gershell raised the price target on Veru to $36 from $25 and maintains an Outperform rating on the shares.
HC Wainwright & Co. analyst Yi Chen maintains Veru with a Buy and raises the price target from $21 to $24.
Veru's price target has been raised by multiple analysts, including Oppenheimer to $36, HC Wainwright to $24, and Jefferies to $33.

Announcements· Jun 4

Veru Inc. (VERU) has entered into a clinical supply agreement with Novo Nordisk (NVO) to support Veru's upcoming Phase 2b PLATEAU study in obesity, evaluating Veru's oral investigational therapy enobosarm in combination with Wegovy.
The agreement grants Novo Nordisk the right of first negotiation for future combinations of enobosarm with GLP-1 medications, and Novo will provide Wegovy for free to Veru's Phase 2b trial.
Canaccord has maintained a Buy rating on Veru with a $25 price target, calling the news a "significant event" that shows enobosarm has "grabbed the attention of one of the two players in the obesity market".

Controversies· Nov 9

An FDA Advisory Panel voted 8-5 against backing Veru's Covid-19 pill, citing concerns over the clinical trial design and data.
The FDA has raised several uncertainties, including baseline imbalances in standard-of-care therapies, potential for unblinding events, and uncertain effects of goals of care decisions on all-cause mortality.
Despite some qualms, FDA staff are considering an EUA with a requirement for another RCT in the same population as a condition of the authorization.

Technical Analysis· Jun 4

$VERU is in a falling wedge pattern and needs to break back over $6 for a potential push to the upside, with a target of $6.5+ above $6.
The 9 EMA trend for $VERU looks ready for a move, with an explosive breakout potentially close.
The daily gap fill for $VERU has been hit, and the stock is ready for a move, with a target of $20+ if it breaks through key resistance levels.

Generated by AI

Community

Of the messages about VERU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	52.17%	41.67%
Newcomers	—	—	47.83%	58.33%

Regulars· Jun 4

$VERU has entered a clinical supply agreement with Novo Nordisk to evaluate the combination of Enobosarm with Wegovy, a $15–$20 billion annualized product.
The news is considered a "significant event" by Canaccord, which reiterated a Buy rating and $27 price target for Veru.
Veru's stock price surged 146% due to the announcement, and the company is expected to break out of resistance with sizzling volume and a rocket RSI.

Newcomers· Jun 5

Many newcomers are focused on the stock's recent surge, with some mentioning the company's partnership with Novo Nordisk and the potential for enobosarm combination therapies.
New investors are weighing in on the stock's potential, with some sharing their own experiences of buying and selling VERU, and others expressing hesitation due to the stock's volatility.
VERU's business model and recent market activity are being explored in depth by some newcomers, who are looking for a deeper understanding of the company's role within the healthcare sector and potential for long-term development.

Generated by AI

Veru

Social

Sep 8

Bullish· Jun 11

Bearish· Jun 11

Earnings· Feb 9

Analysts· Apr 12

Announcements· Jun 4

Controversies· Nov 9

Technical Analysis· Jun 4

Regulars· Jun 4

Newcomers· Jun 5

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

Veru (VERU) Q3 2026 Earnings Call Transcript

Earnings call transcript: Veru posts Q3 2026 EPS beat as PLATEAU trial advances

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru completes enrollment of obesity drug trial with 239 patients

Also Discussed

Veru Inc.

Company Information

Location

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

Veru (VERU) Q3 2026 Earnings Call Transcript

Earnings call transcript: Veru posts Q3 2026 EPS beat as PLATEAU trial advances

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru completes enrollment of obesity drug trial with 239 patients

Also Discussed

Social

Sep 8

Bullish· Jun 11

Bearish· Jun 11

Earnings· Feb 9

Analysts· Apr 12

Announcements· Jun 4

Controversies· Nov 9

Technical Analysis· Jun 4

Regulars· Jun 4

Newcomers· Jun 5